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INTRODUCTION 
With the advent of widespread use of coronary care units in the 
late 1960 's, deaths due to arhythmias in patients with evolving myocar-
dial infarctions were substantially reduced. Left ventricular dysfunc-
tion, as manifest by pulmonary edema and cardiogenic shock, became re-
cognized as the chief cause of in-hospital mortality. Autopsy studies 
revealed that car.diogenic shock occurred when the cumulative amount of 
myocardial necrosis from old and new infarctions exceeded 40% of the 
left ventricle (1,2). More recently, residual ventricular function has 
been shown to be a major predictor of long term survival after myocar-
dial infarction (3). Recognition of these facts has led to a large num-
ber of experimental and clinical studies in which pharmacologic, mechan-
ical or surgical interventions have been employed to reduce the amount 
of myocardial necrosis resulting fran coronary occlusion. 
Stimulation of myocardial beta-1 receptors by catecholamines in-
creases heart rate and contractile function and thereby oxygen consump-
tion. Some studies have proposed that catecholamines augment oxygen 
consumption more than is necessary for the increased external work per-
formed, and thus have an additional direct oxygen wasting effect (4). 
Enhanced cardiac sympathetic nerve activity (5) and marked elevation of 
circulating catecholamine levels have been demonstrated within minutes 
of coronary eccl us ion ( 6). Beta-blockers were thus an obvious first 
choice in early experimental studies (7) and more recent clinical trials 
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(8) designed to limit infarct size after coronary occlusion. 
In current clinical practice, patients with coronary artery di-
sease or hypertension, who are at higher than average risk for myocar-
dial infarction, receive beta-blockers for periods of years. There is a 
weal th of experimental information about the effects of acute intraven-
ously administered beta-blockade on infarct size, hemodynamics and 
arhythmias resulting f'rom coronary occlusion. In contrast, very 1 ittle 
is known about the effects of chronic beta-blockade prior to coronary 
occlusion on these parameters. Investigations performed in animals 
which have received chronic beta-blocker therapy (9) or chronic cardiac 
denervation ( 10) suggest that long term interruption of beta-adrenergic 
influences may confer more protection to ischemic hearts than may be 
achieved with short term adrenergic interruption. This study was de-
signed to compare the effects of acute vs. chronic beta-blockade on myo-
cardial infarct size and hemodynamics in response to coronary occlusion. 
LITERATURE REVIEW 
Modification of Infarct Size - A Historical Perspective 
Experimental studies attempting to measure and modify infarct size 
have substantially improved our understanding of the basic pathophysi-
ology of myocardial infarction. Many different models of myocardial 
infarction and methods of measuring infarct size have been employed and 
later abandoned as knowledge has grown. A few studies are particularly 
noteworthy because they have demonstrated important new concepts which 
serve as the foundation for present experimental and clinical investi-
gations. 
In 1971 Maroko et al. (7) ligated a branch of the left anterior 
descending coronary artery and measured the magnitude of ST-segment ele-
vation and CPK d epl etio n at sites within and remote from the area of 
ischemic injury in anesthetized dogs. They demonstrated; (1) that the 
magnitude of epicardial ST-elevation 15 minutes after coronary occlusion 
predicted the magnitude of cell death (as measured by CPK depletion) 24 
hours later, (2) that interventions which enhanced myocardial contrac-
til ity or heart rate ( isoproterenol, oubain, glucagon, bretyl ium, 
pacing) or depressed coronary perfusion pressure ( hemmorhage) substan-
tially increased EKG and enzymatic indices of myocardial injury, (3) 
that propranolol, which decreases myocardial oxygen consumption by de-
pressing heart rate and contractility, significantly decreased myocar-
dial injury resulting from coronary occlusion, and lastly, (4) that 
3 
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the ability of isoproterenol and propranolol to alter the extent of in-
jury persisted, but was blunted, when they were applied 3 hours after 
coronary occlusion. These were the first studies to demonstrate that 
the extent of injury resulting from coronary occlusion could be altered 
and suggested a time-dependent evolution of myocardial infarction. 
The idea that all cells within a region of evolving myocardial 
infarction did not die simultaneously was demonstrated by Riemer et al. 
( 11). The extent of transmural myocardial necrosis at the level of the 
posterior papillary muscle was examined histologically in anesthetized 
dogs subjected to circumflex coronary occlusions of varying duration. 
They found that myocyte necrosis progressed in a wavefront from endocar-
dium to epicard ium. Irreversible cell death occurred rapidly in the 
subendocardial region but was seen progressively later in the mid-wall 
and subepicardial regions. The relative proportion of transmural myo-
cardium which was ischemic but salvageable at 15 minutes, 40 minutes, 3 
hours and 6 hours after coronary occlusion were 100%, 55%, 33%, and 16% 
respectively. When completed, the process of infarction spared a small 
region of subepicardium. Microvascular injury similarly progressed from 
endocard ium to epicard ium but over a longer period of time. The most 
severe injury occurred in endocard ial reg ions where endothelial swelling 
and degeneration led to vascular occlusion which prevented reperfusion. 
The major contribution of these studies was their definition of a very 
narrow temporal window for therapeutic interventions during evolving 
myocardial infarctions. 
A major problem which hindered early studies was the fact that 
unequivocal gross identification of myocardial infarcts becomes possible 
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only after 24 hours of coronary occlusion ( 12). Thus investigators 
found it necessary to prolong the duration of their studies until the 
processes of cell death and inflammation were sufficiently developed to 
permit visual identification of regions of infarction. Myocardial in-
farctions can be recognized earlier by light and electron microscopy, 
but for practical reasons, these methods 1 imit quanti tation of necrotic 
myocardium to progressively more circumscribed regions (i.e. the pos-
ter ior pa pill ar.y muscle (11)). Epicard ial mapping of ST changes allows 
early identification of ischemic injury at a particular site but does 
not discriminate precisely the borders between normal and ischemic tis-
sue and is only an indirect predictor of subsequent infarction. A sig-
nificant technical advance occurred when macroscopic histochemical 
stains, as originaly described by Nachlas and Shnitka in 1963 (12), were 
rediscovered and popularized by Lie et al. (13) in 1975. They recog-
nized that when myocardial muscle was immersed in colorless solutions of 
certain tetrazolium salts (nitroblue tetrazolium and triphenyl-
tetrazol ium chloride), a deeply colored precipitate was deposited on the 
surface of viable tissue (NBT-blue, TTC-red), while infarcted tissue 
remained unstained. This technique precisely discriminates between in-
farcted and non-infarcted tissue as early as 3 hours after coronary oc-
d usion ( 14). Several studies have shown that both NBT and TTC are as 
accurate as the "gold standards" of histology and electronmicroscopy in 
the identification of infarcted tissue ( 14-16). Klein et al. ( 17) have 
shown that failure of myocardial cells to stain with these tetrazolium 
salts occurs because of the loss of dehydrogenase enzymes or their 
necessary co-enzymes (NADINAIE). Loss of co-enzymes is an earlier bio-
6 
chemical event than loss of dehydrogenases and accounts for the ability 
to identify infarcted muscle within the first hours after coronary oc-
clusion. In comparison with earlier methods of quantitating the size of 
experimental myocardial infarcts, tetrazollium salts allow experiments 
of shorter duration and permit the visual identification and measurement 
of myocardial infar~ts with the accuracy of histology and electron-
microscopy but with much greater ease. 
It had been apparent to early investigators ( 18) and was later 
rediscovered (19) that despite ligations of the same coronary artery at 
a fixed anatomic site in the canine model, the proportion of the left 
ventricle that became infarcted could vary widely among animals. Lowe 
et al. ( 19) were the first to propose that anatomic variation in the 
size and distribution of a given coronary artery was the major reason 
for this phenomenon. They defined the myocardium perfused by a coronary 
artery distal to its site of occlusion as the area at risk for infarc-
tion and suggested that in fare t size should be expressed in relation to 
the size of the risk region. 
A wide variety of methods to measure the size of the "area at 
risk" were developed. Ante-mortem techniques included the injection 
into the left atrium of colored dyes, fluorescent vital stains, or 
technetium-labelled albllllin microspheres which would identify the risk 
region by its failure to take up the dye, fluoresce, or emit radiation 
respectively (20-22). Intracoronary injection of microfil, latex, water 
soluble dyes, or barium sulfate gelatin allowed either direct or 
"defect" definition of the risk region post-mortem (23,19,24,25). 
Regardless of the method employed, a few important new concepts 
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were consistently demonstrated. Widely recognized was the fact that the 
amount of the left ventricle infarcted increased linearly as a function 
of the size of the risk region (19,22,24,25). When the area at risk was 
less than 10-20% of the canine left ventricle, no infarction occurred 
after coronary occlusion (22, 25-27). Pharmacologic interventions could 
shift this relation so that for any size risk region the mass infarcted 
was significantly less (19,28). It was also recognized that as the per-
fusion bed of the occluded coronary became larger, the proportion in-
farcted increased (25). However, even with very large risk regions 
there was always a small region of subepicardium which remained viable. 
The ability of a pharmacologic intervention to salvage ischemic tissue 
depends primarily on the size of the hypoperfused zone (22). Experi-
mental animals with the smallest areas at risk had the greatest re-
duction in danage while those with the largest risk regions had the 
least reduction in the proportion of the risk region infarcted. Ad-
ditionally, spatial differences exist such that the most severe injury 
occurs in basal a'ld subendocard ial portions of the risk region (25, 27). 
An explanation for these regional differences in infarct size was 
first proposed by Lowe et al. ( 19) and actually demonstrated by Jugdutt 
et al. (25). Using radioactive microspheres it was shown that col-
lateral blood flow within the area at risk was highest when the risk 
region was small, in samples taken from the subepicardium, and in that 
part closest to the apex (25, 27). Conceptually, the relationship of the 
size of the area at risk to its collateral blood flow was 1 ikened to 
that of the volume of a sphere to its surface area ( 19). The relative 
proportion of the area at risk receiving collateral flow sufficient to 
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prevent cell death is greatest when the risk region is small (25). In 
apical and subepicard ial regions, which are the surfaces of the sphere 
interfacing with collateral vessels, the proportion of the risk region 
which goes on to infarction is least. 
An additional interesting finding which arose from these studies 
was described by Becker et al. (26). They found that in normal dog 
hearts subjected to coronary occlusion, collateral blood flow to the 
circtrnflex bed was consistently greater than that into the left anterior 
descending bed. Consequent! y when risk regions of equal size were gen-
erated by ligation of a coronary artery the amount infarcted was greater 
after a left anterior descending occlusion than after circtrnflex occlu-
sion. By inference one would expect that interventions designed to 
limit infarct size would be less effective when the left anterior de-
scending is occluded as opposed to the circtrnflex. 
Studies of the type cited thus far have evaluated the effects of 
ischemia and interventions which modify it on quantitative measures of 
cell necrosis. However, no real benefit is achieved if histologic sal-
vage of myocardium is unaccompanied by preservation or restoration of 
contractile function. Tennant and Wiggers (29) first recognized that 
coronary occlusion caused the immediate loss of contraction within the 
ischemic region. Even tho'ugh myocardial function is lost rapidly, cell 
death does not occur unless coronary occlusion is maintained for more 
than 20 minutes (29). Several investigators have recognized that recov-
ery of function after brief periods of ischemia C< 20 minutes) requires 
2-3 days and is associated with gradual improvement of ul trastructural 
and biochemical indices of reversible injury (30, 31 ). Reperfusion after 
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2 hours of coronary occlusion is accompanied by even longer periods of 
functional recovery ( 14 days) which, on a regional basis, is never com-
plete (32). Braunwald has described reversibly injured myocardial mus-
cle as having been "stunned" by an ischemic insult (30). Thus, the im-
provement in regional and global left ventricular function achieved by 
interventions (i.e. reperfusion) which limit infarct size may not be 
manifest for weeks. 
In summary, these investigations have demonstrated that myocardial 
infarction is a dynamic process which can be favorably modified within a 
narrow temporal window. Simple methods exist for accurately assessing 
the anount of necrosis which occurs in laboratory animals. The amount 
of the left ventricle which becomes infarcted and the severity of is-
chemia within the per fusion bed of an occluded coronary artery are 
largely determined by the anount of muscle served by that artery. Myo-
cardium salvaged by reperfusion (and possibly by other interventions) 
regains contractile function only after a period of days to weeks. 
Effects of Acutely Administered Beta-blockade on Experimental and 
Clinical Myocardial Infarction 
Adequate rationale exists for proposing that the presence of beta-
blockade may favorably alter the outcome of myocardial infarction. In 
nl.lllerous experimental studies involving several species, beta-blockers 
have been administered just before or within hours of the onset of myo-
cardial infarction. As might be expected, variations in methods, exper-
imental models, species utilized and the specific beta-blocker given 
have been accompanied by results that at times are conflicting. 
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There are several studies which evaluate the ability of beta-
blockers to protect myocardium subjected to prolonged periods of 
coronary occlusion (i.e. 5 or more hours). As mentioned earlier, Maroko 
et al. (7) demonstrated that administration of propranolol (0. 5-2. O 
mg/kg i.v.) just prior to ligation of the left anterior descending in 
dogs resulted in less ST-elevation at 15 minutes and less CPK depletion 
at 24 hours than seen in control animals. When they performed ligations 
of the circumflex in dogs, Rasmussen et al. (33) found that the propor-
tion of the posterior papillary muscle infarcted after 24 hours was re-
duced :f'rom 85% to 52% in animals given 5 mg/kg of propranolol intra-
arterially 10 minutes before occlusion. When propranolol therapy was 
delayed to 3 hours after ligation, it was less than half as effective as 
pre-treatment. Fox et al. ( 34) investigated the effects of intravenous 
propranolol (0. 5 mg/kg) administered 30 minutes after left anterior des-
cending occlusion in anesthetized dogs. Five hours after the onset of 
infarction they noted significantly less CPK release, less QRS change, 
and more rapid and substantial improvement in radionuclide images of the 
perfusion deficit caused by coronary occlusion. Downey et al. reported 
that administration of 2 mg/kg propranolol at 6 hour intervals beginning 
just after embolization of either the circunflex or anterior descending 
produced substantial salvage of subepicardial ischemic muscle (35). 
Recently, the relative effects of propranolol, timolol and metoprolol on 
infarct size determined 6 hours after left anterior descending ligation 
were compared (36). When administered 15 minutes after coronary occl u-
sion all three agents reduced infarct size as compared with placebo, but 
the beta-1 selective agents were twice as effective. 
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In contrast, a few well done experimental studies are notable for 
their failure to demonstrate protective effects of beta-blockers in myo-
cardium subjected to long periods of ischemia. Peter et al. (37) gave 
high doses of propranolol (5 mg/kg iv) just prior to left anterior des-
cending ligation and supplemented this with an infusion at 1.25 
mg/kg/hr. Identical degrees of CPK depletion were seen in control and 
propranolol treated animals 24 hours later. More recent! y, the compara-
tive effects of metoprolol and pindolol administered at 30 to 90 minutes 
after left anterior descending occlusion on coronary blood flow, left 
ventricular function, and infarct size after 6 hours of ischemia were 
measured (38). Al though both beta-blockers decreased LV dP/dt and meto-
prolol decreased heart rate, neither agent produced changes in infarct 
size or in coronary blood flow as measured by micro spheres. Rogers et 
al. performed the only experimental study of this type in primates. 
They investigated the effects of sotalol on LV function and CPK deple-
tion in baboons 24 hours after LAD ligation, and found no benefit (39). 
Another group of experimental studies have investigated the ef-
fects of acute beta-blockade on infarct size resulting f'rom shorter per-
iods of coronary occlusion (2 hours or less) followed by reperfusion. 
At least 6 different investigations have been performed in anesthetized 
dogs given various beta-blockers prior to or up to 2 hours after coro-
nary ligation (40-45). In comparison with reperfusion alone, substan-
tial additional reductions in infarct size varying f'rom 40-90S have been 
seen. The greatest additional benefit from adding beta-blockade to 
reperfusion occurs when beta-blockade is administered prior to the onset 
of ischemia, and when the time to reperfusion is brief. By diminishing 
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the oxygen requirements of ischemic myocytes beta-blockade delays cell 
death so that more must!le can be salvaged at the time of re perfusion. 
While the literature is more consistent in affirming the salutary 
effects of acute beta-blockade on infarct size when combined with reper-
fusion, two exceptions bear mention. Genth et al. (46) found that pin-
dolol, a beta-blocker with partial agonist activity, when administered 
prior to a 90 minute coronary occlusion with subsequent reperfusion, did 
not alter infarct size in dogs. Because of its intrinsic sympathomi-
metic property, pindolol produced no changes in heart rate and may have 
both blocked and stimulated beta receptors in ischemic muscle. More 
important is a study by Geary et al. done in baboons (47). Al though 
pretreatment with 2 mg/kg of propranolol produced substantial reductions 
in heart rate and LV dP.fdt, no 1 imitation of infarct size was seen when 
2 hows of coronary occlusion were followed by reperfusion. 
The value of urgent beta blockade in patients experiencing acute 
myocardial infarction has been studied in a host of clinical investi-
gations (48-57,8). In contrast to the animal studies cited thus far, a 
number of uncontrolled variables have hindered these investigations. 
Among them are; (1) inter-patient variability in the pathologic cause of 
myocardial infarction, (2) difficulty in accurately measuring the 
duration of ischemia prior to treatment, (3) differences in the coronary 
artery involved, (4) variation in the severity of associated atheros-
clerosis in other coronary arteries, (5) diversity in the presence and 
adequacy of collateral flow, (6) the variable presence and extent of 
prior myocardial infarction, (7) pre-existing left ventricular dysfunc-
tion, and (8) difference in medications received chronically prior to 
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the infarct. Additionally, the ante-mortem methods of measuring infarct 
size in patients that have been employed (serum CPK modelling, surface 
EKG mapping, and planar radionucleide images) are at best indirect and 
semi-quantitative measures of infarct size. 
Despite these limitations, six clinical trials have reported re-
ductions of enzymatic or EKG indices of infarct size (48-54). In 3 
large studies the incidence of primary ventricular fibrillation within 
the first 48 hours of myocardial infarction was significantly reduced by 
treatment with a beta-blocker (55-57). These results are particularly 
remarkable when it is realized that the dose of beta-blockers used have 
generally been one-tenth of that found to limit infarct size in experi-
mental animals. 
Only one major clinical study failed to find a beneficial effect 
of acute beta-blockade on infarct size (8). In that study, propranolol 
was given intravenously and later orally to patients presenting up to 18 
hours after the onset of chest pain. No improvement in enzymatic, EKG 
or radionucleide estimates of infarct size was found. The results of 
that study are most likely explained by the fact that fewer than 2 per 
cent of the patients studied received propranolol within 4 hours after 
the onset of symptoms. 
Myocardial Ischemia and Infarction After Chronic Cardiac Denervation or 
Long-term Beta-blockade 
Two separate lines of investigation suggest that chronic inter-
ruption of adrenergic stimulation may induce secondary adaptive changes 
in cardiac muscle that would be beneficial during periods of ischemia. 
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Resting myocardial oxygen consumption 2 weeks after cardiac denervation 
(58) or ventricular sympathectomy (59) was approximately 50j less than 
that in sham-operated dogs and was accompanied by significant reductions 
in myocardial blood flow (59-61). Despite increasing anounts of exter-
nal work, both myocardial oxygen consumption and coronary blood flow 
continued to be one-half that of normal animals (59). As a consequence 
of this enhancement in the efficiency of energy utilization, Barber et 
al. (61) found that the minimal blood flow needed to prevent the death 
of ischemic cardiac muscle was substantially lower after chronic cardiac 
denervation. A major reduction in coronary collateral resistance (62) 
and a marked increase in collateral blood flow after coronary occlusion 
(63) were reported after chronic ventricular sympathectomy. Not sup-
risingly, a number of different studies have described dramatic reduc-
tions in infarct size, myocardial dysfunction and arhythmias resulting 
f'rom coronary occlusion in chronically denervated animals ( 1O,60, 61, 64-
66). 
Jones et al. (10) and Barber et al. (61) found that infarct size 
following mid-LAD ligation was reduced in animals which underwent car-
diac denervation immediately before coronary occlusion. However, sig-
nificant further reductions in infarct size were seen in animals dener-
vated 2-4 weeks prior to coronary occlusion. Thomas et al. (64) com-
pared the effects of coronary occlusion on contractile function in dogs 
with normally innervated, acutely denervated and cl'u"onically denervated 
hearts. Epicardial contractile force in the ischemic region was mini-
mally depressed in chronically denervated hearts but no similar protec-
tion was provided by acute denervation. 
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With section of cardiac sympathetic nerves, Wallerian degeneration 
of postganglionic fibers occw-s. As a result, myocardial catecholamine 
levels drop to less than 2% of normal in the first week after cardiac 
denervation ( 67). No similar depletion of catecholamines would be 
anticipated in acutely denervated hearts subjected to coronary oc-
clusion. Local release of norepinephrine in response to ischemia might 
be responsible for the intermediate preservation of ischemic myocardium 
and regional function in acutely denervated animals. However, Jones et 
al. ( 10) administered propranolol and i:tientolamine prior to coronary 
occlusion in their acutely denervated dogs to prevent stimulation of 
adrenergic receptors by locally released catecholamines. They still 
found that chronic denervation was significantly more effective in lim-
iting infarct size. This finding implies that metabolic alterations or 
enhanced collateral flow after prolonged withdrawal of adrenerg ic neural 
stimulation are more important mechanisms for protection of ischemic 
myocardium. 
In distinct contrast to previous studies is a recent investigation 
by Lavallee et al. (68). They reported that ligation of the circumflex 
produced higher left ventricular end-diastolic pressures, diminished 
collateral blood flow and larger myocardial infarctions in chronically 
denervated dogs than was seen in normally innervated animals. They at-
tributed the difference between their findings and those of earlier in-
vestigations to the fact that most previous studies were done in anes-
thetized animals while they produced coronary occlusions in concious 
animals. However, not all prior studies demonstrating beneficial ef-
fects of cardiac denervation on the cow-se of subsequent myocardial in-
16 
farction have been done in anesthetized animals. Schaal et al. (65) 
found that chronic cardiac denervation abolished the ventricular tachy-
cardia seen in 9 of 10 control animals, after ligation of the anterior 
descending, in conscious dogs. 
Most experimental studies have shown that cardiac denervation 
favorably affects infarct size, myocardial contractile function and 
arhythmias after coronary occlusion. In addition, prolonged denervation 
seems to produce adaptive changes which afford the ischemic heart added 
protection. The salutary effects of acute denervation during ischemia 
are similar to that achieved by acute beta-blockade ( 1 O). A series of 
experiments suggest that chronic beta-blockade may induce many of the 
added benefits seen with chronic denerv ation. 
In rabbits treated with propranolol for 4 or more weeks, electron-
mic:roscopy revealed substantially fewer mitochondria per cell than in 
untreated animals (69). In addition, the relative volume occupied by 
capillaries was increased while the volume of the interstitial space was 
diminished. Besides demonstrating that the distance for diffusion of 
oxygen from capillary to cell membrane is shortened, this study implies 
a lower basal oxygen consumption after prolonged beta-blockade. The 
same treatment :regimen in another study (70) was found to markedly de-
press the activities of dopamine beta-hydroxylase and tyrosine hydrox-
ylase (the rate limiting enzyme in norepinephrine synthesis) in sympa-
thetic ganglia. Depression of norepinephr ine synthesis by prolonged 
beta-blockade might result in lower myocardial norepinephrine content 
and thus decrease catecholamine mediated myocardial injury during is-
chemia. Becker et al. (71) have shown that chronic beta-blocker therapy 
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produces a functional alteration in the relation between beta receptors 
and adenylate cyclase. They found that prolonged beta-blockade l"educed 
adenylate cyclase activity such that the Clllount of cyclic AMP produced 
for any given extracellular concentration of catecholamine was signifi-
cantly diminished. Wexler (72) found that 7 days aftel" withdrawal of 
long-tenn propranolol therapy, massive doses of isoproterenol failed to 
produce the extensive myocardial necrosis and mortality seen in rats not 
previously treated with beta-blockers. This protection was present at a 
time when tissue and serl.111 propranolol levels would be unmeasurable. 
A few studies have evaluated the effects of long-term beta-
blockade in models of myocardial ischemia. Manning et al. found that 
both propranolol and oxprenolol, when administered orally for 3 weeks to 
rats, resulted in an increased incidence of functional recovery after 
periods of global ischemia in isolated perfused heart preparations (73). 
Post-ischemic cellular levels of creatine phosphate and glycogen recov-
ered rapidly and more completely in animals previously beta-blocked than 
in controls. This beneficial action was seen as long as 48 hours after 
beta-blocker withdrawal when serum d:rug levels were undetectable. 
Nayler et al. (9) treated rabbits with propranolol for five days and 
then subjected their hearts to 60 minutes of hypoxic perfusion in a 
Langendol"f preparation. They found much lower levels of CPK in the 
coronary effluent and pronounced presel"vation of mitochondrial function 
in the hearts pretreated with pl"opranolol as compal"ed with controls. No 
functional inhibition of the chronotl"opic response to isopl"otel"enol 
could be demonstrated mol"e than 18 hours aftel" the last dose of pl"o-
pranolol. However, dramatic protection resulting f'rom beta-blocker 
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therapy was seen as long as 72 hours after cessation of beta-blocker 
adm in ist:r atio n. 
Th:ree investigations have evaluated the effects of chronic beta-
blockade on the course of subsequent coronary occlusion. Of these, the 
only study in large animals was that of Menken et al. (74). They re-
ported that five days of atenolol therapy increased the ventricular fib-
rillation threshold and decreased the incidence of ventricular fibril-
lation after proximal circunflex occlusion in dogs. Hearse et al. (75) 
perfo:rmed LAD ligations in isolated perfused wo:rking rat hearts {»'"e-
viousl y treated with propranolol or acebutolol for 3 weeks. One hour 
after coronary occlusion, cardiogreen dye was infused into the patent 
coronaries and the hearts were immediately frozen. In this study, the 
area at risk was identified by its failure to take up the green dye due 
to inadequate antegrade or collateral coronary perfusion. They found 
that chronic beta-blockade resulted in substantially smaller risk re-
gions than seen in controls, presumably on the basis of enhanced col-
lateral flow. However, the severity of ischemia within the ischemic 
region, as measured by high energy phosphate levels, was not different 
between groups. Campbell et al. (76) ligated the left main coronary for 
one hour in rats {»'"etreated with oxprenolol. When coronary occlusion 
occurred 1 hour after the last dose of oxprenolol, the incidence of ven-
tricular fib:rillation and mortality were less than in control animals, 
but no difference in infarct size was p:resent. When the same expe:ri-
ments were perfo:rmed 16 hours after the last dose of oxprenolol, no 
benefit was evident. The failure of chronic beta-blocker therapy to 
limit infarct size in this model can probably be attributed to the 
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severity of the ischemic insult. On the average, 48% of the ventricle 
was in farcted one how after left main occlusion. In addition to the 
fact that a very large J)J"oportion of the ventricle was ischemic, the 
severity of cellular injwy within this region was undoubtedly augmented 
by the rapid heart rates in these animals, which often exceeded 400 
beats per minute. 
Only one clinical study has attempted to evaluate the effects of 
prior beta-blocker therapy on infarct size in man (76). In an investi-
gation involving 45 patients with acute myocardial infarction, 10 of 
whom had chronically received any of a variety of beta-blockers, enzym-
atic measures of infarct size were made. The time to the onset of 
enzyme :release and the time to peak enzyme release were both signifi-
cantly delayed by p:rior beta-blockade, although eventual infa:rct size 
was not changed. This data was interpreted as suggesting that beta-
blockade had delayed the onset of cell death in those patients. In con-
trast, 3 large mul tic enter t:rial s involving timolol, propranolol and 
metoprolol have all documented enhanced survival and a reduced incidence 
of sudden cardiac death and reinfarction anong patients receiving these 
beta-blockers on a chronic basis after myocardial infarction (78-80). 
The mechanism fo:r this protection is unknown. 
METHODS 
Drug Treatment and Confirmation of Beta-blockade 
Mongrel dogs employed in the study were divided into three treat-
ment groups; group 1 (N•10) served as controls, group 2 (N•12) was 
intravenously beta-blocked just prior to coronary occlusion and group 3 
(N•11) was chronically beta-blocked prior to coronary occlusion. Group 
3 animals :received 80 mg of nadolol twice daily for 16 days. They were 
restricted to a na:r:row weight range (19-21.5 kg, mean•20.1 kg) to ap-
proximate an 8 mg/kg daily dose of nadolol. Nadolol is a non-selective 
beta-blocker which is 2 to 4 times more potent than p:rop:ranolol, but 
lacks any direct myocardial depressant effects (81 ). It is free of in-
trinsic sympathomimetic activity and was chosen because its half life of 
elimination in dogs (4-5 h:rs, 82) is longer than that of any other beta-
blocker. Sixteen days of o:ral therapy were given because a similar 
period produced marked protection after cardiac dene:rvation (10,61,64). 
In one animal, 24 hours after a single 80 mg oral dose of nadolol, the 
chronot:ropic response to a 2 ug!kg bolus of isoprote:renol was inhibited 
by 51S. In 5 additional experiments performed in our lab, this treat-
ment regimen inhibited the chronotropic response to the same bolus of 
isoproterenol by 93S (71) and 87S when measured 12 hours after the last 
oral dose of nadolol on days 7 and 14 of therapy, :respectively. This 
test dose of isoproterenol exceeds the chronotropic stimulus produced by 
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maximal neural stimulation as demonstrated by experiments in our lab and 
by Led sane et al. ( 84). 
It was our intention that the degree of beta-blockade in the two 
drug-treated groups be equivalent at the time of coronary occlusion. In 
this manner, differences in the degree of salvage of ischemic myocardium 
in the two groups would not reflect dose-dependent differences in the 
level of beta-blockade, but rather, effects achieved by different dura-
tions of therapy. Therefore, acutely beta-blocked animals received suc-
cessive boluses of nadolol intravenously until they had less than a 10 
beat per minute increase in heart rate in response to 2 ug/kg isoproter-
enol given intravenously. Coronary occlusion in the chronically beta-
blocked dogs were performed approximately 12 hours after the last oral 
dose of nadolol. These animals were also given incremental doses of 
nadolol intravenously until they had less than a 10 beat per minute in-
crease in heart rate in response to the test dose of isoproterenol. In 
both drug-treated groups, titration of the degree of beta-blockade with 
i .v. nadolol was performed approximately 15 minutes prior to coronary 
occlusion. 
Surgical Pr epar atio n 
Animals in all treatment groups were an est he ti zed with pentobar-
bital and a tracheostomy tube was inserted for ventilation. The animals 
were ventilated with a Harvard respirator and arterial blood gases were 
measured periodically to maintain pH in the range 7.35-7.45, with p02 
greater than 60. The right femoral vein and artery were isolated for 
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venous access and measurement of arterial pressure. The left femoral 
artery was used for insertion of a Millar transducer-tipped catheter 
which was advanced into the left ventricle for measurement of LVEDP, 
left ventricular peak systolic pressure, and dP/dt. ECG leads II, III, 
and AVF were monitored to reflect changes in the posterior wall. A bio-
tachometer triggered by the ECG measured heart rate. Epicard ial tem-
perature was measured and maintained in the range 37-39 degrees celsius. 
All hemodynamic and ECG measurements were recorded on a Gould 2800S re-
corder. The first 30 minutes of the post-occlusion period were recorded 
on magnetic tape for later analysis of arhythmias. 
The chest was opened through the fourth left intercostal space, 
and the pericardium opened with a small incision at the base of the 
heart. A segnent of the circumflex coronary artery was isolated within 
1-2 cm of its origin, proximal to the first major marginal branch. 
Experimental Protocol 
In all animals control hemodynamic and ECG measurements were ob-
tained 5 minutes prior to occlusion. In drug-treated animals, these 
pre-occlusion measurements were made after administration of i .v. 
nadolol. Coronary occlusion was achieved by tying a silk ligature about 
the vessel. In addition, an atraumatic occluder was placed on the 
circumflex distal to the ligature when animals failed to manifest epi-
cardial cyanosis or ST elevation. Hemodynamic and ECG measurements were 
made 15 minutes, 30 minutes, 1 hour, and hourly thereafter for the dur-
ation of the six hour period. Three hours after occlusion, 0.5 mg/kg 
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nadolol was given intravenously to drug-treated animals. 
During the last hour of the experiment all animals received 5000 
units of heparin, and a right carotid to circumflex shunt was placed to 
permit reperfusion of the previously ischemic region (Figure 1). The 
carotid end of the shunt was created with a 50 cm length of tygon tubing 
containing a cannulating-type electranagnetic flow probe. The tip of a 
5 (!UI length of BF infant feeding tube was inserted into the circumflex 
distal to the occluding ligature but proximal to any major branches. 
After six hours of coronary occlusion, reperfusion through the shunt was 
begun and shunt flow measured. 
Measurement of Area at Risk and Infarct Size 
After 15 minutes of reperfusion 1 ccfkg of a 1.5i solution or· 
Evans blue in Ringer's solution was injected into the left atrium. Be-
cause of the longer transit time for blood to reach the circumflex re-
gion via the shunt, a brief (2-3 second) interval occurred during which 
the c i:rcumfl ex bed received dye-f'ree blood while the remainder of the 
heart was blue stained. At this time the hearts were fibrillated 
electrically and Ringer's solution was infused into the circumflex can-
nula (6 cclmin) to keep dye out of the circumflex region while the heart 
was excised. 
Once removed, the heart was sliced in a "bread loaf" manner into 8 
to 12 sections, in an apex to base direction. The right ventricle and 
atria were trimmed away and each slice blotted dry and weighed. The 
unstained regions within each ring represented the anatanic perfusion 
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FIGURE 1 
THE CAOOI'ID 10 CIRCUMFLEX SHUNT 
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bed of the circumflex artery distal to the site of the occluding liga-
ture, and was designated the area at risk for necrosis. The lateral 
margins of the area at risk were marked from epicardiurn to endocardium 
on both surfaces of each slice with a felt tipped pen (Figure 2) . 
To measure the size of the infarcted area each slice was soaked 
for 20 minutes in a U solution of triphenyl tetrazoliurn chloride (TTC) 
in phosphate buffer (23, 24). Non-infarcted tissue on the surface of 
each slice was stained a brick red by the tetrazoliurn dye, while in-
farcted tissue failed to stain. Although TTC staining masked the Evans 
blue-stained tissue, the margins of the area at risk, as defined by the 
felt pen markings, remained visible (Figure 3). Color slides of both 
surfaces of each slice were made and later projected onto an Apple 
graphics tablet for planimetry (using an Apple II+ computer and soft-
ware). From these images the :relative sizes of the left ventricular 
cross sectional area, the area at risk and the area infarcted were 
identified for both surfaces of each slice. From these areas the ab-
solute weights of each :region were calculated and surnmated for the en-
tire le ft ventricle. 
Sta ti sties 
Differences between groups in mortality and the incidence of ven-
trieular fibrillation, ventricular tachycardia, or high degree AV blook 
were compared using Fisher's Exact Test. Comparisons between groups in 
the number of PVCs during the first 30 minutes of coronary occlusion 
were evaluated using a one-way analysis of variance. This same statis-
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FIGURE 2 
THE METHOD FDR IDENTIFYING THE 
AREA AT RISK 
FIGURE 2. This is a photograph of the basal surface of a ring of 
ventricular muscle at the level of the papillary muscles after infu-
sion of Evan's blue dye. The unstained tissue in the left half of 
this figure is the perfusion bed of the circumflex coronary artery 
(i.e. the area at risk). Black lines marking the lateral margins of 
the area at risk were placed with a felt-tipped pen. Note an exten-
sive region of subendocardial halX)rrhage within the area at risk. 
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FIGURE 3 
THE MITTHOD OF IDENI'IFYING THE 
AREA INFARCTED 
FIGURE 3. This photograph was taken after the same slice of ven-
tricular muscle had been incubated in a solution of TIC. Note that 
a brick red precipitate was deposited on the cut surface of muscle 
outside the area at risk. In addition, the precipitate was also 
deposited on myocardium in the epicardial and lateral portions of 
the area at risk, indicating that it was not infarcted. A large re-
gion of infarcted muscle involving the endocardial half of the area 
at risk is identified by its failure to deposit the precipitate. 
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tical analysis was also employed to evaluate differences between treat-
ment groups in body weight, left ventricular mass, and the mass and pro-
portion of the left ventricle at risk. T-tests with a Bonferroni cor-
rection were used to determine the significance of differences in in-
farct size between groups {85, 86). Linear regressions were calculated 
using the method of least squares. Hemodynamic data were evaluated 
using a two-way analysis of variance with replications followed by 
Duncan's Multiple Range Test. This permitted canparisons between groups 
at any individual time and comparisons within any group overtime. All 
values are expressed as the mean ± the standard error of the mean. 
RESULTS 
Mortality and Arhythmias 
A total of 33 animals were studied. One control animal and 2 
acutely beta-blocked animals developed high degree AV block associated 
with profound hypo tension and died within 2 hours of coronary occlusion. 
Measurement of the size of the risk region and infarct size were not 
possible in these animals. Hemodynamic data obtained from these experi-
ments were excluded. One control animal developed ventricular fibril-
lation 18 minutes after circumflex ligation and was defib:rillated within 
25 seconds, with prompt restoration of hemodymanics to the levels seen 
prior to fibrillation. The incidence of ventricular tachycardia 
(defined as 3 or more consecutive ventricular extrasystoles at a :rate 
greater than 100 beats per minute) was 1oi, 36% and 60% in the three 
groups, respectively. These differences were not statistically signifi-
cant. Similarly, no difference was seen between groups in the number of 
ventricular extrasystoles recorded during the first half-hour following 
circumflex occlusion. 
Effects of Acute and Chronic Beta-blockade on Infarct Size 
Measurement of the size of the risk region and of the myocardium 
infa:rcted was possible in 30 of the dogs studied. The data obtained is 
presented in Table 1. No difference was present between groups in body 
29 
30 
Table 1 
RISK REGION AND INFARCT SIZES 
Acutely Chronically 
Controls f3-blocked f3-blocked 
(n=9) (n=lO) (n=ll) 
Infarct mass 33.1±3.0 24.7±3.7 21.4±4.3 
(g) (18.9-45.1) (2.4-39.8) (0.4-38.0) 
Risk region mass 48.2±2.9 46.1±2.9 47.1±2.0 
(g) (38.0-59.1) (28.6-59.7) (37.9-56.9) 
LV mass 103.0±4.5 105.7±4.6 103.6±2.6 
(g) (88. 6-117. 7) (82.6-133.6) (91. 9-114 .4) 
Infarct/LV 32.0±2.6 22.7±3.2 20.6±4.2 
(%) (21-45) (3-38) (0-41) 
Risk region/LV 46.9±2.4 43 .4±1.4 45.5±1.8 
(%) (35-59) (35-51) (34-54) 
Infarct/risk region 67.7±2.9 51. 5±6. 6 43.5±8.3* 
(%) (50-77) (8-79) (1-80) 
Values are expressed as the mean ± s.e.m. (range in parentheses) 
*p < .05 as compared with the control group. 
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weight (group I • 19.2 ± 0.2 kg, group II • 20.4 ± 1.0 kg, group III • 
20. 1 ± O. 3 kg), left ventricular mass, or in the mass of the risk re-
gion. While the proportion of the left ventricle at risk in each group 
was simila:r, a stepwise decrease in the mass infarcted and in the per-
cent of the left ventricle infarcted was seen in groups II and III re-
spectively. When expressed as a proportion of the risk region, infarct 
size was reduced 24j by acute beta-blockade and 36j by chronic beta-
blockade. The latter result was statistically significant as compared 
with the control group. However, differences in infarct size between 
the acutely beta-blocked animals and either of the other two groups did 
not :reach statistical significance. 
In Figure 4 the percent of the left ventricle infarcted is plotted 
as a function of the percent of the ventricle at risk, for the control 
group. A linear correlation with an R value of 0.90 was found (Y•.96x-
12. 98, P < .01 ). By extrapolation, no infarction would be predicted 
with risk :regions smaller than 14j of the left ventricle in this group. 
Simila::r linear correlations were performed for acutely (Y•1. 58x-45. 71, 
R•0.70, P < .05) and chronically (Y•1.72x-57.38, R•0.69, P < .05) beta-
blocked animals. In general, the lines for these two groups were 
shifted rightward, such that the mass of risk region necessary to pro-
duce an infarct of a given size was successively greater after acute and 
chronic beta-blockade. However, the much lower correlation coefficients 
highlight the wide variability of infarct size in the drug treated 
groups. 
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Degree of Beta-blockade after Prolonged Oral Therapy and Infarct Size in 
Chronically Beta-blocked Animals 
All animals in g:roup 3 received the same daily dose of nadolol for 
the same duration of time, and were of similar weights. However, varia-
bil ity was present in the ch:ronot:ropic :response to the test dose of 2 
uglkg of isoproterenol (0-30 bpm, mean•22 bpm) 12 hours after the last 
oral dose of nadolol. Similar variation was present in the supplemental 
dose of i.v. nadolol (0-1. 3 mglkg, mean•O. 5 mgfkg) given just prior to 
circumflex ligation to inhibit the increase in heart :rate after isop:ro-
terenol to less than 10 bpm. On the average, this supplemental dose of 
i.v. nadolol was less than half that given to acute! y beta-blocked an i-
mals (1-2.5 mgfkg, mean•1.3 mgfkg). When the percent of the left ven-
tricle infarcted was plotted as a function of the ch:ronot:ropic :response 
to isoproterenol, a statistically significant linear corr.elation was 
found (Y•0.76x + 4.27, R•0.60, P < .05). Thus, the ability of nadolol 
to limit infarct size after chronic oral therapy was in part a function 
of the deg:ree of beta-blockade at the end of the 16 day treatment per-
iod. This relationship was seen despite the fact that supplemental 
doses of i.v. nadolol we:re given just p:rio:r to coronary occlusion to 
ensure equivalent degrees of beta-blockade in all drug treated animals. 
Hemodynamics Before and After Coronary Occlusion 
Several measured and derived hemodynamic pa:ramete:rs obtained be-
fore and at three different times after circumflex ligation are pre-
sented in Table 2 and Figures 5 -7. At all times heart rate in either of 
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the drug treated groups was significantly less than in control animals. 
Over the duration of the experiment heart :rate averaged 25 bpm higher in 
control animals. Six hours after coronary ligation heart :rate was 21 
bpm greater than prior to coronary occlusion (p < .OS) in this group. 
In contrast, heart rate was unchanged or minimally increased during the 
experiment in groups II and III, :respectively. 
Pre-occlusion left ventricular end diastolic pressures were 
similar in all groups. However, by 6 hours after circumflex occlusion 
it was significantly elevated in control and acutely beta-blocked ani-
mals, as compared with pre-occlusion values. LVEDP rose minimally in 
chronically beta-blocked animals and was significantly less than in 
either of the other two groups at 6 hours (p < .05). 
There was no difference in dPldt among groups prior to coronary 
occlusion. Over the duration of the experiment, it :rose in control ani-
mals and declined in drug treated animals. Six hours after circumflex 
1 igation it was 36% and 26% lower, in groups II and III :respectively, 
than in group I (p < • 05). 
Mean arterial pressure and left ventricular peak systolic pressure 
were similar in all groups and essentially unchanged during the experi-
ment as compared with pre-occlusion values. Changes in rate pressure 
product pa:ralelled those in heart rate. At 6 hours it was 49% and 35% 
greater in control animals than in acutely or chronically beta-blocked 
animals, :respectively (p < .05). 
Table 2 
HEMODYNAMIC DATA 
HR MAP LVEDP LVPSP dP/dt 
TIME GROUPS (BPM) 
-
(nunHg) (mmHg) (mmHg) (mmHg/sec) RPP/1000 
Prior to I 146.4+2.9 112+A.l 4 .4+1. 2 117. 7+6.5 1803+105 17·.'3+1. l 
CFX II 129.7+4.2* 109.8+4.l 6.1:+1.7 119. 6+5 .o 1764+142 15.4+o.4 
Occlusion III 128.1+3.8* 110 •. 6+3.9 4.l+o.8 121. 7+4.1 1758+115 15.6+o.8 
- -
15 min I 148.7+2.5 96.7+7.7 8.3+2.0 108+8.9 1778+189 16.5+2.2 
after II l24.6+4.0* 92.7:+5.3 10·.0+2. 2+ 101. 8+4 .8+ . 1549+108 12.6+o. 7* 
CFX Occl III 130. 5+4.1• 99.3+3.6 8. 2+1.1 105.6+1.8 1598+123 14.l+o.7 
- -
2 hrs I 158.9+6.2 112.8+5.4 8. 7+1.5 121. 8+6. l 1976+125 19.5+1.6 
after II 120+5.5* 113.6+6.3 12.4+2.3 120.7+5.3 1517+89* 14 .6+1. l* 
CXF Occl III 138.1+3.5# 110.4+3.7 9.0+1. 3 119. 9+3. 2 1649+81 16.5t-0.6 
* 
6 hrs I 167.4+6.8+ 107.4+6.l 15.9+1.9+ 124.7+5.5 2020±112 21.1+1.5+ 
after II 129.6+6.5• 97.9+4.6 15.8+2.6+ 108.9+3.7 1297±95+ 14. 2+i. O* 
CXF Occl III 142.1+5.3* 99.5+6.4 9.5:±1. 2~ 111.4+5. 3 1491+142• 1S.8+o.8* 
* p < .05 as compared with the control group 
+ p < .05 as compared with the preocclusion value 
H p < .05 as compared with the acutely B-blocked group 
HR = Heart Rate, MAP = Mean Ar~erial Pressure, tVEDP = Left Ventricular End Diastolic 
Pressure, LVPSP = Left Ventricular Peak Systolic Pressure, dD/dT = The Rate of Rise of 
Left Ventricular Pressure~ RPP/1000 = Rate Pressure Product t 1000 
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FIGURE 4. The percent of the left ventricle infarcted increased as a 
linear function of the size of the area at risk. Extrapolation of this 
line to the X intercept indicates that no infarction \\Ould be expected 
with risk regions snaller than 14% of the ventricle. 
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DISCUSSION 
Differences in Infarct Size and Potential Sources of Variability within 
Groups 
In this study acute and chronic beta-blockade resulted in incre-
mental decreases in the proportion of the area at risk which infarcted 
after circumflex ligation. While a modest degree of variation in in-
farct size was seen in control animals, drug treated animals exhibited 
much less uniformity. Some dogs in both drug-treated groups evolved 
infarcts as large as any in control animals while others derived marked 
protection from beta-blockade. As a result, only the reduction in in-
farct size achieved by prolonged beta-blockade was statistically signif-
icant as compared with the control group. In addition, infarct sizes in 
acutely and chronically beta-blocked animals did not significantly dif-
fer from each other. 
The reason for the wide variability in the extent of myocardial 
injury among animals in groups II and III is not clear. In a recent 
co-operative study, a group of investigatiors found that much of the 
variation in infarct size in canine models of myocardial infarction 
could be attributed to three independent variables (90). The size of 
the area at risk, collateral blood flow, and myocardial oxygen consump-
tion (estimated by the rate-pressure product) accounted for roughly 70%, 
15%, 5S of this variation, respectively. To control for the most impor-
tant of these three variables, infarct size is commonly normalized 
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for the size of the risk region, as was done in the present study. In-
consistencies in accurate measurement of the risk region could produce 
sufficient experimental error to make comparisons of normalized infarct 
size between groups difficult. Two pieces of data suggest that this was 
not the case. Figure 3 demonstrates that the technique employed in this 
study accurately reproduces the finding of other investigators; 
(19,22,24,25) the amount of the left ventricle infarcted increases line-
arly as a function of the size of the perfusion bed of the occluded 
coronary artery. In addition, the proportion of the left ventricle per-
fused by the circumflex, as defined by this technique, is very similar 
to previously reported values (24, 87-90). Therefore, variation in in-
farct size within or between groups cannot be ascribed to errors in 
measuring the risk region. Moreover, the average size of the area at 
risk and variability about these means were similar in all three groups. 
The fact that collateral blood flow into an ischemic region can 
differ considerably between experimental animals has been observed re-
peatedly (25,26,90,91). Its relative importance in determining the size 
of experimental myocardial infarctions has only recently been deter-
mined. Once the area at risk has been controlled for, soi of the re-
maining variability in infarct size in canine hearts is due to differ-
ences in collateral blood flow (90). In the present study collateral 
blood flow was not measured. It would be anticipated that biologic 
variation in collateral flow would affect all three groups equally if 
the number of animals studied was sufficiently large. The much wider 
range in infarct size in drug-treated animals suggests that substantial 
reductions in infarct size may only have occurred when collateral blood 
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flow exceeded a minimal critical value. In the absence of significant 
collateral flow, neither acute nor chronic beta-blockade would be suffi-
cient to maintain cellular viability for 6 hours after coronary occlu-
sion. This hypothesis is supported by the finding that beta-blockers 
have been unsuccessful in reducing infarct size in species which lack a 
significant coronary collateral circulation (39,47). 
The severity of myocardial injury resulting from coronary occlu-
sion depends upon the mismatch between oxygen supply and demand. In 
combination, the area at risk, collateral blood flow and the rate-
pressure product have been found to account for 90j of the variability 
in infarct size seen in animals (90). However, of these three, varia-
bility in myocardial oxygen consumption was the least important. In 
this experiment variation within groups in rate-pressure product was not 
different and fails to account for the wider range of infarct size in 
groups II and III. 
By design, differences between animals in the degree of beta-
blockade immediately prior to and during the 6 hour period of circumflex 
occlusion were minimized. A large dose of a very potent beta-blocker 
was chosen and a supplemental dose was given before one half-life of 
elimination. Additionally, circumflex ligation in groups II and III 
were performed only when sufficient beta-blockade was present to inhibit 
the chronotropic responses to a large test dose of isoproterenol. It 
therefore seems unlikely that variation in the degree of beta-blockade 
during the ischemic period contributed significantly to differences in 
infarct sizes among drug-treated animals. 
However, despite equivalent beta-blockade during coronary oc-
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clusion, infarct size in chronically beta-blocked animals was signifi-
cantly correlated with the degree of beta-blockade (i.e. the inhibition 
of the chronotropic response to isoproterenol) at the end of the 16 day 
treatment period. Differences between animals in the absorption, metab-
olism and elimination of nadolol are likely to have resulted in dispari-
ty in the magnitude of beta-blockade during this 16 day period. This 
was illustrated by the range of responses to the test dose of isopro-
terenol. This finding suggests that "dose dependent" adaptive changes 
may have occurred in the hearts of chronically beta-blocked animals 
which conferred additional protection from ischemia induced injury. 
Whether these adaptive changes were favorable alterations in metabolism 
or in collateral blood flow is unknown. 
In summary, although a number of potential sources for the wide 
variation in infarct size among acutely and chronically beta-blocked 
animals exist, two appear to have been particularly important. In both 
groups variability in collateral blood flow may have served a permissive 
function such that significant reduction in infarct size may only have 
occurred when collateral flow exceeded a critical minimal value. In the 
chronically beta-blocked animals the degree of beta-blockade during the 
16 day treatment period was found to be an independent predictor of in-
farct size. 
Mechanisms for the Protective Effect of Acute and Chronic Beta-Blockade 
In animal models of myocardial infarction, dramatic increases in 
cardiac sympathetic nerve activity (5) and in circulating levels of 
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plasma catecholamines (6) have been demonstrated shortly after coronary 
occlusion. Striking elevations of plasma norepinephrine and epinephrine 
concentrations have similarly been reported in patients with evolving 
infarcts (92). By enhancing the disparity between myocardial oxygen 
supply and consumption, catecholamines have been shown to augment the 
severity of cellular injury in ischemic tissues (7,93). Beta-blockers 
have been shown in experimental and clinical myocardial infarction to 
decrease myocardial oxygen consumption and to favorably shift myocardial 
metabolism from lactate production to lactate extraction (94-96). 
Catecholamine mediated stimulation of beta-1 receptors leads to 
increases in both heart rate and contractility. If decreasing heart 
rate alone was the only important action of beta-blockers, they would 
still achieve the dual benefits of decreasing myocardial oxygen consump-
tion and increasing the time available for diastolic perfusion of the 
coronary circulation. However, beta-blockers have been shown to protect 
ischemic tissue independent of their negative chronotropic effects. 
Hilis et al. (97) observed that when propranolol was administered to 
dogs subjected to LAD occlusion, the resulting rise of intramyocardial 
pC02 was 43j less than in control experiments. Virtuallly the same pro-
tection was seen in animals paced to prevent beta-blocker mediated de-
creases in heart rate. Similarly, Armstrong et al. (98) found that when 
atrial pacing was performed in a group of patients with coronary artery 
disease the threshold to angina and the electrocardiographic and meta-
bolic indices of ischemia were all attenuated. 
The enhanced sympathetic activity that accompanies acute myocar-
dial infarction may also effect the severity of myocardial ischemia 
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through indirect, extracardiac actions. Catecholamines are lipolytic 
and elevated levels of circulating free fatty acids have been demons-
trated during myocardial infarction (92,99). With elevation of free 
fatty acids, substrate utilization within ischemic tissue shifts un-
favorably from the anaerobic metabolism of glucose towards the oxidation 
of free fatty acids (100). Pharmacologic inhibition of catecholamine-
sensitive lipases has been shown to reduce infarct size in a canine 
model (101). By inhibiting the action of epinephrine on adipocytes, 
beta-blockers have been shown to reduce circulating free fatty acids 
during myocardial infarction in man (92). The ability of beta-blockers 
to reduce oxygen consumption in ischemic tissues may partially be due to 
this action. 
Another proposed effect of beta-blockers is that they improve 
oxygen supply to ischemic myocardium by increasing collateral blood flow 
(102). While some studies have reported enhanced collateral flow (102) 
and an increase in the ratio of endocardial to epicardial flow (103), 
others have found no beneficial changes in regional myocardial blood 
flow when beta-blockers were administered during experimental myocardial 
infarction (37, 38). 
In this experiment, measurement of the major determinants of myo-
cardial oxygen consumption were made before and after coronary oc-
clusion. Pre-occlusion values of left ventricular end diastolic pres-
sure, mean arterial pressure, and dP/dt were not different between 
groups. Heart rate, however, was lower in beta-blocked animals. Over 
the course of the 6 hour experiment heart rate rose progressively in 
control animals while changing little in the other groups. This sug-
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gests that the control group was exposed to progressively increasing 
adrenergic stimulation in response to circumflex ligation. 
Similarly, coronary occlusion produced directionally opposite 
changes in dP/dt in control and beta-blocked animals. Despite the fact 
that 32 ± 2.6S of the left ventricle was infarcted in control animals, 
the expected decline in dP/dt was not seen. Instead dP/dt rose and was 
significantly greater than in drug treated animals at 6 hours. This 
suggests that a marked augmentation of contractility occurred in the 
non-ischemic myocardium of control animals. It was of sufficient magni-
tude that dP/dt, an index of overall left ventricular contractile func-
tion, failed to decline as anticipated. Higher heart rates, elevated 
left ventricular end diastolic pressures, and greater levels of sympa-
thetic tone in the control group, together may account for this pheno-
menon. In combination, they also resulted in significantly larger myo-
cardial infarcts as compared with chronically beta-blocked animals. 
All the potential mechanisms cited above for the salutary effects 
of beta-blockade in acute myocardial infarction are pertinent to both 
groups of drug-treated animals evaluated in this study. As discussed 
earlier, a series of studies have demonstrated alterations of myocardial 
ultrastructure, metabolism efficiency of energy utilization and collat-
eral blood flow afer prolonged interruption of cardiac adrenergic stimu-
lation. These effects could potentially confer added protection from 
ischemia induced injury to chronically beta-blocked hearts. Although 
infarct size was not statistically different between drug treated 
animals in this study, left ventricular end diastolic pressure was sig-
nificantly less in chronically beta-blocked animals 6 hours after cir-
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cumflex ligation. 
In the setting of acute myocardial infarction, loss of contractile 
function by ischemic cardiac muscle leads to diminished ventricular 
emptying during systole and elevated end diastolic volumes. In ad-
dition, impaired relaxation of ischemic myocardium during diastole re-
sults in diminished left ventricular compliance. Together systolic and 
diastolic dysfunction result in elevation of left ventricular end dias-
tolic pressure. In the present study, systolic ventricular function in 
chronically beta-blocked animals, as measured by dP/dt, was no different 
than that in acutely beta-blocked animals and was less than that in the 
control group 6 hours after coronary occlusion. The finding that left 
ventricualar end diastolic pressure was significantly lower in chronic-
ally beta-blocked animals than in either of the other tw~ groups sug-
gests that left ventricular compliance may have been substantially 
better in this group. However, since left ventricular compliance was 
not directly measured in this study, differences in compliance between 
groups can only be inferred. 
Comparisons with Earlier Studies 
No previously published study has compared the effects of im-
mediate and long-term beta-blockade on infarct size and hemodynamics 
resulting from experimental coronary artery occlusion. In two studies, 
isolated, working hearts of small animals have been subjected to periods 
of global ischemia or hypoxia at various times after cessation of pro-
longed beta-blocker therapy. Manning et al. (73) found that the number 
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of hearts that recovered mechanical function and the post-ischemic 
cellular levels of creatine phosphate and glycogen were significantly 
enhanced in rats previously treated with either propranolol or 
oxprenolol. Prolonged pre-treatment with propranolol resulted in less 
CPK release, less mitochondrial calcium accumulation and enhanced mito-
chondrial function in rabbit hearts subjected to 60 minutes of hypoxic 
perfusion by Nayler et al. (9). In both of these studies, the protec-
tive effects of prior beta-blockade were seen at times when residual 
drug levels or functional beta-blockade could not be demonstrated. They 
suggest that there are secondary consequences of long-term beta-blockade 
which are beneficial during myocardial ischemia. 
Two studies, both performed in rats, have evaluated the effects of 
chronic beta-blockade on injury resulting from coronary ligation. 
Hearse et al. (75) occluded the LAD in isolated, working hearts of rats 
previously treated with acebutolol or propranolol for 2-3 weeks. After 
1 hour of ischemia cardiogreen dye was infused into the aortic root to 
identify all myocardium perfused by native or collateral vessels. They 
found that the ischemic region, defined by the absence of green dye, was 
substantially smaller in the hearts of chronically beta-blocked animals. 
This implies that collateral blood flow in these hearts was enhanced. 
However, high energy phosphate content within the ischemic region was 
not different between groups and infarct size was not measured. Re-
cently Campbell et al. (76) reported that chronic oxprenolol treatment 
did not reduce the size of myocardial infarcts after ligation of the 
left main coronary artery in rats. It is doubtful that any intervention 
would favorably alter infarct size with such a large proportion of the 
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ventricle ischemic or in the presence of the marked tachycardia they 
reported (400+ bpm). 
Direct comparison between the present study and those cited above 
are difficult. None of these studies have investigated the effects of 
acute and chronic beta-blockade on infarct size in the same model. In 
addition, heart rate, left ventricular internal diameter and wall thick-
ness (all important determinants of myocardial oxygen consumption) are 
drastically different in rat and rabbit models from that seen in the 
canine heart. In experimental design, the present study is much closer 
to those which have evaluated the effects of cardiac denervation on in-
farct size and myocardial function in anesthetized dogs. 
Jones et al. (10) ligated the apical portion of the anterior de-
scending and compared the proportion of the left ventricle infarcted in 
control animals, those denervated just prior to coronary occlusion, and 
those denervated 2 weeks previously. They found sequential substantial 
reductions in infarct size with acute and chronic cardiac denervation. 
Using a similar model with coronary occlusion at the same site, Barber 
et al. (61) reproduced these findings. In contrast, the abilities of 
acute and chronic beta-blockade to limit infarct size in the present 
study were less dramatic. This difference might be attributed to the 
substantially larger risk regions in this study. The area at risk was 
not measured in the former studies but it appears to have been no larger 
than 20-25% of the left ventricle. In comparison, the area at risk was 
nearly twice as large in this investigation. It has previously been 
demonstrated that even in control animals no infarction frequently 
occurs with risk region less than 15-20% of the ventricle (22,25-27). 
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Additionally, the ability of an intervention to limit infarct size in-
creases substantially as the area at risk becomes smaller (22). 
The relative effects of acute and chronic cardiac denervation on 
myocardial contractile function after coronary occlusion were described 
by Thomas et al. (64). They found substantial equivalent reductions in 
epicardial contractile force after coronary ligation in control and 
acutely denervated hearts. However, the depression of regional myocar-
dial function seen in chronically denervated hearts was only one third 
that seen in other groups. Although regional myocardial function was 
not measured in the present study, left ventricular end-diastolic pres-
sure was significantly lower in chronically beta-blocked animals than in 
other groups 6 hours after coronary occlusion. 
Recently Lavallee et al. (68) reported larger myocardial infarcts 
and higher left ventricular end diastolic pressures after proximal 
circumflex ligation in concious, chronically denervatd dogs. The reason 
for the disparity between these results and earlier investigations of 
the effects of cardiac devervation on infarct size, myocardial function 
and arhythmias in anesthetized animals is not clear. However, the work 
of Lavallee et al. suggests that an avenue for future investigation 
might include the repitition of the present study in conscious animals. 
SUMMARY 
In the present study, the relative effects of acute and chronic 
beta-blockade on infarct size and hemodynamics after circumflex ligation 
in anesthetized dogs were investigated. In comparison with control 
animals, mean infarct size was smaller in both groups of drug-treated 
animals, but only the reduction in infarct size achieved by chronic 
beta-blockade was statistically significant. While infarct size among 
the two groups of beta-blocked animals were similar, left ventricular 
end diastolic pressure was significantly less 6 hours after coronary 
occlusion in chronically beta-blocked animals. The salutary effects of 
beta-blockade in this study can partially be attributed to protection 
from enhanced adrenergic tone after coronary occlusion. Despite the 
fact that all drug treated animals had similar and substantial degrees 
of beta-blockade during coronary occlusion, infarct size in chronically 
beta-blocked animals was independently correlated with the degree of 
beta-blockade during the previous 16 days. 
From these findings we conclude that long term beta-blockade re-
sults in at least as great a reduction in infarct size as does acute 
beta-blockade. However, left ventricular hemodynamics during myocardial 
infarction, as evidenced by lower end-diastolic pressures, appear to be 
better preserved after chronic beta-blockade. In addition, the protec-
tive effect of prolonged beta-blockade during subsequent periods of myo-
cardial ischemia is related to the degree of beta-blockade during the 
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previous treatment period. 
These findings support the current clinical practice of prolonged 
beta-blocker therapy in patients at high risk for subsequent ischemic 
events. In addition, they suggest that patients may benefit from re-
ceiving the largest dose of beta-blockers tolerated without side 
effects. 
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